Should dupilumab treatment for atopic dermatitis patients be suspended or modified during the COVID-19 pandemic?
The current EAACI statement on the usage of biologicals in the context of COVID-19 advices no change of therapy in non-infected individuals and to withhold/delay the application of biologicals for a minimum of two weeks or the resolution of the disease in case of SARS-CoV-2 infection.44 This is based on expert opinion in the light of missing data and may be adapted if more information becomes available.